Market Place
Sourcing Support
Hikma`s Generics Ephedrine Sulfate Receives Approval in US
11 Oct 2024 //
FDA
Jazz, Hikma must face `reverse payment` claims over narcolepsy drug
27 Aug 2024 //
REUTERS
Hikma Participates In Naloxone Training With Congressman
20 Aug 2024 //
PR NEWSWIRE
KLOXXADO Naloxone Nasal Spray Shelf-Life Extended To 36 Months
15 Aug 2024 //
PR NEWSWIRE
FDA Issues Form 483 to Hikma Injectables USA
26 Jul 2024 //
FDA
Hikma Extends Pain Drug Recall Due To Potential Sedative Presence
23 Jul 2024 //
FIERCE PHARMA
FDA Issues Form 483 to Hikma Pharmaceuticals USA
09 Jul 2024 //
FDA
After Stock crash and Staff cuts, Amarin wins bid to revive Vascepa patent
26 Jun 2024 //
FIERCE PHARMA
Teva launches generic version of Novo Nordisk`s diabetes drug Victoza
25 Jun 2024 //
REUTERS
Hikma Pharms Biologic Liraglutide Receives Tentative Approval in US
21 Jun 2024 //
FDA
Enforcement Report - Week of May 29, 2024
29 May 2024 //
FDA
Hikma`s Generic Edaravone Receives Approval in the U.S.
06 May 2024 //
FDA
Collegium Authorized Generic Deal with Hikma for Nucynta®
29 Apr 2024 //
GLOBENEWSWIRE
Teva, like Hikma, accuses Amarin of hoarding Vascepa ingredient
30 Mar 2024 //
FIERCE PHARMA
Enforcement Report - Week of March 27, 2024
27 Mar 2024 //
FDA
Hikma`s Generic Sodium Acetate Receives Approval in the U.S.
15 Mar 2024 //
FDA
Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus
21 Feb 2024 //
PR NEWSWIRE
Hikma`s Generic Levetiracetam Receives Approval in the U.S.
12 Feb 2024 //
FDA
Hikma`s Generic Hydromorphone Hydrochloride Receives Approval in the U.S.
09 Feb 2024 //
FDA
Hikma announces US launch of COMBOGESIC® IV
05 Feb 2024 //
PR NEWSWIRE
Hikma to pay $115M in cash, $35M in donations to settle opioid claims
02 Feb 2024 //
ENDPTS
Guardant Health and Hikma Partner to Offer Cancer Screening Tests
08 Jan 2024 //
BUSINESSWIRE
Hikma marks two-year anniversary of KLOXXADO® launch
03 Oct 2023 //
PR NEWSWIRE
Korea`s SK Biopharma enters MENA through strategic partnership with Hikma
21 Aug 2023 //
BIOSPECTRUM ASIA
Rakuten Medical and Hikma Sign Licensing Agreement for Alluminox Platform
10 Aug 2023 //
PR NEWSWIRE
Hikma Ventures invests in Octave Bioscience, a precision care platform
26 Jul 2023 //
PR NEWSWIRE
Shares in Pfizer rivals Hikma, Fresenius rally after tornado hits factory
20 Jul 2023 //
REUTERS
Hikma exceeds 150 injectable medicines in US with launch of Dobutae Injection
15 Jun 2023 //
PR NEWSWIRE
Enforcement Report - Week of May 24, 2023
24 May 2023 //
FDA
Hikma Sees Signs Of A Bounceback For Generics
02 May 2023 //
PHARMAINTELIGENCE
Hikma`s Generic Clindamycin Phosphate Receives Approval in the U.S.
05 Apr 2023 //
FDA
Hikma`s Generic Gemcitabine Hydrochloride Receives Approval in the U.S.
07 Mar 2023 //
FDA
Hikma accuses Amarin of suppressing generic versions of heart pill
22 Feb 2023 //
REUTERS
Hikma`s Generic Regadenoson Receives Approval in the U.S.
02 Feb 2023 //
FDA
Hikma`s Generic Morphine Sulfate Receives Approval in the U.S.
12 Jan 2023 //
FDA
Hikma`s Generic Medroxyprogesterone Acetate Receives Approval in the U.S.
05 Jan 2023 //
FDA
Enforcement Report - Week of January 4, 2023
04 Jan 2023 //
FDA
Hikma Pharma launches Xyrem’s generic in US
04 Jan 2023 //
EXPRESS PHARMA
Hikma introduces generic Xyremin US market
03 Jan 2023 //
PHARMABIZ
Hikma & Junshi Biosciences sign exclusive licensing agreementfor cancer treatment drug toripalimab
27 Dec 2022 //
PRESS RELEASE
Junshi Biosciences & Hikma Sign Exclusive Licensing Agreement for Toripalimab
26 Dec 2022 //
GLOBENEWSWIRE
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
08 Dec 2022 //
GLOBENEWSWIRE
Hikma`s Generic Fludrocortisone Acetate Receives Approval in the U.S.
27 Oct 2022 //
FDA
Hikma, Teva, Sandoz Report Short Supply of Amoxicillin in US
25 Oct 2022 //
BLOOMBERG
Hikma appoints Deneen Vojta as a Director
13 Oct 2022 //
PRESS RELEASE
Glenmark`s partner Hikma launches specialty drug Ryaltris in US
30 Aug 2022 //
ECONOMICTIMES
Hikma launches RYALTRIS seasonal allergic rhinitis nasal spray in the US
30 Aug 2022 //
PRNEWSWIRE
Class 2 Medicines Recall: Hikma Pharmaceuticals USA Inc, Lorazepam
30 Aug 2022 //
GOVUK
Hikma`s Generic Vigabatrin Receives Approval in the U.S.
29 Aug 2022 //
FDA
Hikma`s Generic Linezolid Receives Approval in the U.S.
22 Aug 2022 //
FDA
Enforcement Report - Week of August 17, 2022
17 Aug 2022 //
FDA
Hikma`s Generic Neostigmine Methylsulfate Receives Approval in the U.S.
13 Jul 2022 //
FDA
Hikma Pharmaceuticals Generic Naloxone HCL Receives Approval in the U.S.
10 Jun 2022 //
FDA
Hikma completes acquisition of Custopharm
21 Apr 2022 //
PRNEWSWIRE
FTC requires Hikma to let go of steroid drug, post $375M Custopharm acquisition
20 Apr 2022 //
ENDPTS
Hikma Ventures invests in Tact.ai
29 Mar 2022 //
PRNEWSWIRE
